Insilico Medicine and Eli Lilly expanded their strategic deal for AI-discovered oral therapeutics, with terms described as $115 million up front and up to about $2.75 billion in “biobucks” tied to regulatory and commercial milestones. The arrangement includes rights for Lilly to develop, manufacture, and commercialize certain preclinical Insilico candidates. The report says the deal covers assets related to oral therapeutics and references Lilly’s existing ties to Insilico’s GLP-1 program, including that one GLP-1 candidate has been out-licensed to an undisclosed partner. It also notes Insilico CEO Alex Zhavoronkov characterized Lilly as the best partner in relevant disease areas. For biotech professionals, the transaction underscores how large pharma continues to scale AI-originated pipelines via commercialization options and milestone-linked economics, moving beyond licensing of single lead programs toward broader portfolio carve-outs.